Work at Aston University has led to the identification of tissue transglutaminase (TGM2) inhibitors potentially useful for the treatment of fibrosis, thrombosis, cancer, AIDS, inflammation, transplant rejection, neurodegenerative and autoimmune diseases, among others.
Exelixis Inc. has synthesized fused pyrazole derivatives acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
A University of California patent describes new inhibitors of GTPase KRAS, particularly KRAS G12D mutant, reported to be useful for the treatment of cancer.
Insilico Medicine Inc. has disclosed substituted thiazole compounds acting as cyclin-dependent kinase (CDK) inhibitors potentially useful for the treatment of cancer.
Work at Shanghai Institute of Organic Chemistry has led to the identification of new receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors. They are described as potentially useful for the treatment of ischemia-reperfusion injury, Parkinson’s disease, autoimmune diseases, glaucoma, traumatic brain injury, inflammatory disorders, bacterial infections and lysosomal storage diseases, among others.
Janssen Pharmaceutica NV has synthesized new 1,6-naphthridine compounds acting as probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).
Innovo Therapeutics Inc. has patented new pyrazole derivatives acting as caspase-3 inhibitors and potentially useful for the treatment of pulmonary hypertension.
Sitala Bio Ltd. has prepared new indole derivatives acting as complement factor B (CFB) inhibitors. They are thus reported to be useful for the treatment of age-related macular degeneration, schizophrenia, atypical hemolytic uremic syndrome, membranous nephropathy, myasthenia gravis, paroxysmal nocturnal hemoglobinuria, diabetic retinopathy and rheumatoid arthritis, among others.
Researchers from Children’s Hospital Los Angeles and the University of Southern California filed for protection of a pacemaker with a unique shape and configuration which is low profile.
Theranib Inc. has divulged retinal dehydrogenase 1 (ALDH1A1; RALDH1) and/or retinal dehydrogenase 2 (ALDH1A2; RALDH2) and/or aldehyde dehydrogenase family 1 member A3 (ALDH1A3; RALDH3) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
RSS
